Romo increased BMD across eGFR subgroups vs Pbo. Reduction in new vertebral fractures not affected by eGFR. https://t.co/HMkREcwoQj #ACR19 @RheumNow plenary#2730 #ACRbest https://t.co/9ojwhmmZxx
Links:
Efficacy and Safety of Romosozumab vs Placebo Among Patients with Mild-to-Moder…
http://ow.ly/Wb4450x3Eos
Nov-12-2019
